CRISPR Therapeutics (CRSP) currently has six named programs in clinical trials. See why I think CRSP stock is a speculative buy for aggressive growth investors.
Published May 14, 2021 National Institutes of Allergy and Infectious Diseases. (2016). Human natural killer cell [Micrograph]. Retrieved from Flickr.
Dive Brief:
Fate Therapeutics on Thursday reported new results from two early-stage studies testing two types of experimental leukemia treatments that use natural killer cells, an emerging form of cancer immunotherapy.
Four of nine patients who received one Fate NK cell therapy showed evidence of a response, as did one of three who got a different type of NK cell therapy. There were no instances of the neurological or immune-related side effects seen with other forms of cell therapy and there were also no side effects that would prevent testing of higher doses, according to the company.
Dive Brief:
For the last several years, Vertex and CRISPR Therapeutics have been co-developing a potential cure for two blood disorders. On Tuesday, the companies said they amended their agreement so that Vertex takes on more of the associated costs, but also more of the profits should the therapy come to market.
The new agreement directs 60% of development costs and profits from future sales to Vertex, reflecting a 10% increase in both figures. CRISPR is now responsible for 40% of costs and would receive 40% of the profits. The revised terms also hand CRISPR a $900 million upfront payment, with the potential for $200 million more upon the first approval of the therapy, known as CTX001.